Bone Diseases (Bone Disease)

Diseases of BONES.
Also Known As:
Bone Disease; Disease, Bone; Diseases, Bone
Networked: 3566 relevant articles (201 outcomes, 368 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Osteoporosis
3. Bone Resorption
4. Breast Neoplasms (Breast Cancer)
5. Multiple Myeloma


1. Terpos, Evangelos: 31 articles (10/2015 - 09/2003)
2. Body, Jean-Jacques: 19 articles (09/2015 - 01/2003)
3. Coleman, Robert E: 19 articles (05/2013 - 02/2003)
4. Lipton, Allan: 18 articles (09/2015 - 09/2002)
5. Coleman, R E: 13 articles (02/2013 - 01/2000)
6. Dimopoulos, Meletios A: 12 articles (10/2015 - 10/2006)
7. Kalantar-Zadeh, Kamyar: 11 articles (10/2014 - 01/2008)
8. Vanderkerken, Karin: 11 articles (07/2009 - 01/2003)
9. Hofbauer, Lorenz C: 10 articles (10/2015 - 04/2003)
10. Sezer, Orhan: 10 articles (10/2015 - 03/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bone Diseases:
1. DiphosphonatesIBA
2. ibandronic acid (Boniva)FDA Link
3. Vitamin DFDA LinkGeneric
4. CalciumIBA
5. zoledronic acid (zoledronate)FDA Link
6. Parathyroid Hormone (Parathormone)IBA
7. pamidronate (APD)FDA LinkGeneric
8. hydroxide ionIBA
9. AluminumIBA
10. Clodronic Acid (Clodronate)IBA

Therapies and Procedures

1. Parathyroidectomy
2. Renal Dialysis (Hemodialysis)
3. Drug Therapy (Chemotherapy)
01/01/2009 - "Translational medicine or research, an emerging discipline on the frontier of basic science and medical practice, has the potential to enhance the speed and efficiency of the drug development process through the utilization of pharmacogenetics and pharmacogenomics. Pharmacogenetics is the study of genetic causes of individual variations in drug response whereas pharmacogenomics deals with the simultaneous impact of multiple mutations in the genome that may determine the patient's response to drug therapy. The utilization of these methods in the drug development process may therefore identify patient sub-populations that exhibit more effective responses and/or an improved benefit/risk profile upon treatment. The authors provide examples of the use of pharmacogenetics and pharmacogenomics in the fields of cardiovascular, pulmonary, oncological, and bone diseases and also highlight the potential economic value of their development."
11/01/2015 - "Recent advances in drug therapy for metastatic bone diseases are changing the indications for surgicaltreatments. "
07/01/2014 - "The results support the concept that chemotherapy may not be necessary for limited bone disease. "
06/01/2014 - "Myeloma bone disease represents a threefold therapeutic problem: (i) per se because of the associated morbidity, mortality and the accompanying decrease of quality of life, (ii) as survival space for (residual) myeloma cells after primarily successful chemotherapy and subsequently necessary chemotherapeutic treatment, and (iii) the occurrence of bone lesions in asymptomatic patients is the most common cause for the initiation of treatment to avoid myeloma-induced fractures. "
08/15/2013 - "Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors."
4. Transplantation (Transplant Recipients)
5. Kidney Transplantation